The Long-term Follow-up (LTFU) core supports follow-up of patients receiving hematopoietic cell transplantation (HCT) on the various protocols of this Program Project. The LTFU Core aims to ensure complete follow-up of patients undergoing transplantation at the City of Hope Cancer Center, in order to identify detailed information on the incidence and potential risk factors for delayed cardiopulmonary dysfunction, gastrointestinal, renal, reproductive or endocrine dysfunction and subsequent cancers. The Core aims to identify groups at increased risk for the development of these complications, and make recommendations for screening patients identified to be at increased risk. The LTFU Core members include the Core Director (Dr. Smita Bhatia), Dr. Roberto Rodriguez (Staff Physician, Hematopoietic Cell Transplant Program), a Nurse Coordinator and two Clinical Research Assistants (CRAs). The LTFU Core staff has significant expertise in establishing and following large cohorts of cancer survivors and addressing survivorship issues. The LTFU Core has developed and utilized a customized data-collection instrument and database for follow-up and documentation of all potential complications occurring in patients undergoing HCT. Mechanisms are currently in place for ensuring annual follow-up, data collection and data entry for patients undergoing HCT and surviving one or more years. The overall goal of this core is to improve the quality of long-term survival of patients undergoing allogeneic or autologous transplantation for hematologic malignancies, through early identification of complications, identification of """"""""high risk"""""""" groups, and recommendations for screening and/or interventions for prevention of these adverse outcomes. The core also aims to develop risk-based, exposure-related guidelines for long-term follow-up of HCT survivors. The development of these guidelines will allow early identification of exposure-related late complications, potentially allowing for early intervention with resultant improved quality of life and decreased complicationrelated healthcare costs. Thus, the LTFU core is ideally suited to ensure optimum follow-up and systematic data collection of patients undergoing HCT at City of Hope, and will be a vital component to the successful conduct of outcomes-based research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-28
Application #
8111820
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
28
Fiscal Year
2010
Total Cost
$216,006
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications